The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study.

Responder analyses In the responder analyses, numerically fewer patients treated with FCM had a clinically meaningful deterioration (≥5-point decline in the KCCQ-12 OSS), and a greater proportion of patients had a clinically meaningful improvement in the KCCQ-12 OSS at Weeks 12 and 24, compared with the placebo group, although these results did not reach statistical significance ( Figure 3 A and C ).

also in 111,027 other papers